The Role of Inflammatory Processes in Development and Treatment of Depression (INFLAME-D)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03920475|
Recruitment Status : Completed
First Posted : April 19, 2019
Last Update Posted : April 19, 2019
|Condition or disease||Intervention/treatment|
|Depressive Disorder Depression Inflammation||Drug: Sertraline or venlafaxine Diagnostic Test: Immune parameters|
The study investigates the influence of inflammatory processes on the development and the course of uni- and bipolar depression. It is assumed, that the concentrations of certain inflammatory proteins have an influence on the development of depression, its clinical severity, the response to treatment and the risk of relapse. To verify this hypothesis, a total of 145 patients, which were hospitalized für treatment of a depressive disorder in the study centers in Germany, Italy and France, were screened according to the criteria set out in the study protocol. Finally, 104 patients with moderate to severe depressive symptoms were included in the study. The severity of the symptoms was classified using well-established clinical rating scales like MADRS and HAMD17. All enrolled patients were treated according to the recommendations of the DGPPN treatment guidelines.
In order to make drug-induced changes in the serum concentrations of the examined proteins as comparable as possible, it was determined in advance, that all patients should be treated with either sertraline (first choice) or venlafaxine (second choice) as an oral antidepressant. Apart from that, the antidepressive therapy, ie psychotherapy and similar procedures, had not been standardized. The treatment of study participants did not differ from the treatment of other patients hospitalized because of depression, who did not participate in the study. The patients were examined for the presence and severity of depressive symptoms at the time of study enrollment, as well as after 4 and 8 weeks, using standardized clinical test procedures. In addition blood was taken. In the serum of the patients, the concentrations of specific inflammatory proteins were measured using Cytometric Bead Array and ELISA and then correlated with the clinical data. The investigated proteins include high-sensitivity CRP, Interleukin 4, Interleukin 6, Interleukin 12, TNF-α, Eotaxin, CD54, Interferone-gamma and MCP-1.
|Study Type :||Observational|
|Actual Enrollment :||104 participants|
|Official Title:||An Investigation of the Role of Inflammatory Processes in the Development and Treatment of Idiopathic Unipolar and Bipolar Depression in Patients With Moderate to Severe Depressive Symptoms.|
|Actual Study Start Date :||August 5, 2015|
|Actual Primary Completion Date :||March 6, 2018|
|Actual Study Completion Date :||March 6, 2018|
Patients with depression, meeting inclusion criteria, who needed antidepressant treatment and received either sertraline or venlafaxine.
Drug: Sertraline or venlafaxine
Patients were treated as needed with sertraline or venlafaxine following the official guidelines, starting with a dose of 25 mg/d or respectively 37,5 mg/day. The starting dose could be increased during the course of the treatment as clinically needed according to guide lines.
Diagnostic Test: Immune parameters
Serum was taken before, during an after treatment for measurement of different immune parameters.
- Change in severity of depressive symptoms [ Time Frame: 4 and 8 weeks after enrollment in the stuy ]measurement of depressive symptoms using the Montgomery-Åsberg Depression Rating Scale
- Changes in serum-concentration of inflammatory proteins [ Time Frame: 4 and 8 weeks after enrollment in the stuy ]measurement of inflammatory proteins as listed in description of the study
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03920475
|Study Director:||Martin Schäfer||Kliniken Essen-Mitte|